Topics covered: Trial design, Stocks to avoid., Role of the FDA, Relevance of PEG multiples, Potential blockbuster drugs, Partnerships, Medicare Modernizaion Act, Management team analysis, M&A Activity, IPO outlook, Industry risks, Industry fund flows, Consolidation, Cardiovascular market, Big Pharma versus biotech, ASCO
